Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

IPO Update: Values Slip As Four More Biopharma Firms Go Public In October

stock

Related Content

Scrip's Rough Guide To CRISPR Gene Editing

Jun 28 2016

Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?

Feb 04 2016

Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash

Jul 27 2015

Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash

Oct 27 2015

Roundup: Three Chinese Deals To Put On Your Radar

Jan 21 2015

Bayer And CRISPR Form Cutting Edge Gene Editing JV

Dec 22 2015

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves

Sep 29 2016

IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

May 08 2016

Related Companies

Myovant Sciences Ltd.

Ra Pharmaceuticals, Inc.

CRISPR Therapeutics AG

Entero Therapeutics, Inc.

Editas Medicine

Intellia Therapeutics, Inc.

Bayer AG

Vertex Pharmaceuticals Incorporated

Takeda Pharmaceutical Co. Ltd.

Pfizer Inc.

Cancer Prevention Pharmaceuticals, Inc.

AC Immune SA

Novan, Inc.

Protagonist Therapeutics, Inc.

Gemphire Therapeutics, Inc.

Astellas Gene Therapies

Syros Pharmaceuticals, Inc.

Selecta Biosciences, Inc.

Clearside Biomedical, Inc.

Moleculin Biotech, Inc.

Reata Pharmaceuticals, Inc.

Merus N.V.

PhaseRx, Inc.

Outlook Therapeutics, Inc.

Spring Bank Pharmaceuticals Inc.

Spyre Therapeutics, Inc.

Corvus Pharmaceuticals, Inc.

HUTCHMED (China) Limited

Syndax Pharmaceuticals, Inc.

Proteostasis Therapeutics, Inc.

AveXis, Inc.

BeOne Medicines Ltd.

Additional Topics

Commercial Business Strategies BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window